

References

1. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocytopenia are significantly influenced by morphologic diagnosis: An international study. *J Clin Oncol*. 2011;29:3179-3184.
2. Mughal TI, Vaddi K, Sarlis NJ, Verstovsek S. Myelofibrosis-associated complications: Pathogenesis, clinical manifestations, and effects on outcomes. *Int J Gen Med*. 2017;7:89-101.
3. Savona MR. Are we altering the natural history of primary myelofibrosis? *Leuk Res*. 2016;38:1004-1012.
4. Rumi E, Pietra D, Pascutto C, et al, for the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. *Blood*. 2014;124:1062-1069.
5. Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. *Leukemia*. 2014;28:1472-1477.
6. Vannuchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. *Leukemia*. 2013;27:1861-18619.
7. Guglielmelli P, Lasho TL, Rotunno G, et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. *Leukemia*. 2014;28:1804-1810.
8. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. *Blood*. 2009;113:2895-2901.
9. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). *Blood*. 2010;115:1703-1708.
10. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. *J Clin Oncol*. 2011;29:392-397.
11. Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: Mutation-Enhanced International Prognostic Scoring System for transplantation-age patients with primary myelofibrosis. *J Clin Oncol*. 2018;36:310-318.
12. Tefferi A, Guglielmelli P, Lasho TL, et al. MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for primary myelofibrosis. *J Clin Oncol*. 2018;36:1769-1770.
13. Barbui T, Barosi G, Bigegard G, et al, on behalf of European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. *J Clin Oncol*. 2011;29:761-770.
14. Verstovsek S, Gotlib J, Mesa RA, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. *J Hematol Oncol*. 2017;10:156. Published online 2017 Sep 29. doi: 10.1186/s13045-017-0527-7.

15. Palandri F, Palumbo GA, Bonifacio M, et al. Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. *Leuk Res.* 2018;74:86-88.
16. Palandri F, Palumbo GA, Bonifacio GA, et al. Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis. *Oncotarget.* 2017;8:79073-79086.
17. Menghrajani K, Boonstra PS, Mercer JA, et al. Predictive Models for Splenic Response to JAK-inhibitor Therapy in Patients With Myelofibrosis. *Leuk Lymphoma.* 2018; Sep 20:1-7 [E-pub ahead of print].
18. Patel KP, Newberry KJ, Luthra R, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. *Blood.* 2015;126:790-797.
19. Kröger NM, Deeg JH, Olavarria E, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. *Leukemia.* 2015;29:2126-2133.
20. US Food and Drug Administration. FDA approves fedratinib for myelofibrosis. Available at: <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fedratinib-myelofibrosis>.
21. Pardanani A, Harrison CN, Cortes JE, et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial. *JAMA Oncol.* 2015;1:643-651.
22. Harrison CN, Schapp N, Vannuchi AM, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): A single-arm, open-label, non-randomised, phase 2, multicentre study. *Lancet Hematol.* 2017;4:e317-e324.
23. Harrison CN, Schaap N, Vannuchi AM, et al. Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study. ASCO 2019. Abstract 7057.
24. Asshoff M, Petzer V, Warr MR, et al. Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. *Blood.* 2017;129:1823.
25. Harrison CN, Vannuchi AM, Platzbecker U, et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): A randomized open-label, phase 3 trial. *Lancet Haematol.* 2018;5:e73-e81.
26. Mesa RA, Kiladjian J-J, Catalano JV, et al. SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-naïve patients with myelofibrosis. *J Clin Oncol.* 2017;35:3844-3850.
27. ClinicalTrials.gov. A study of momelotinib versus danazol in symptomatic and anemic myelofibrosis patients. Available at: <https://clinicaltrials.gov/ct2/show/NCT04173494?term=MOMENTUM+momelotinib&draw=2&rank=1>.
28. CTI Biopharma. CTI BioPharma provides update on investigational agent pacritinib [press release]. February 8, 2016. Available at: <https://cbc.gcs-web.com/news-releases/news-release-details/cti-biopharma-provides-update-investigational-agent-pacritinib>

29. CTI BioPharma. CTI BioPharma announces removal of full clinical hold on pacritinib [press release]. January 5, 2017. Available at: <https://cbc.gcs-web.com/news-releases/news-release-details/cti-biopharma-announces-removal-full-clinical-hold-pacritinib>.
30. Mesa RA, Vannucchi AM, Mead A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. *Lancet Haematol*. 2017;4(5):e225-e236.
31. Mascarenhas J, Hoffman R, Talpaz M, et al. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial. *JAMA Oncol*. 2018;4:652-659.
32. Gerds AT, Savona MR, Scott BL, et al. Results of PAC023: a randomized phase 2 dose-finding study and determination of the recommended dose of pacritinib. ASH 2019. Abstract 667.
33. ClinicalTrials.gov. A phase 2/3 study of pacritinib in patients with primary myelofibrosis, post polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis (PACIFICA). Available at: <https://clinicaltrials.gov/ct2/show/NCT03165734?term=PACIFICA&draw=4&rank=2>.